New fluoroquinolones in community-acquired pneumonia: a clinical and economic evaluation

Metge C J, Vercaigne L, Carrie A, Zhanel G G

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
This report aims to critically review and compare, both clinically and economically, the new fluoroquinolones for the empiric treatment of community-acquired pneumonia (CAP).

Authors' conclusions
Analysis of the trials on an intention-to-treat basis, which preserves the value of randomization and prevents the introduction of bias, indicates that the orally-administered new fluoroquinolones offer no statistically significant additional clinical successes when compared to current comparative antibiotics for the empirical treatment of CAP. The 'evaluable subjects' analysis found new fluoroquinolones to be slightly more effective in treating individuals diagnosed with CAP than comparative antibiotics. However, considering the limitations associated with the available evidence, we conclude that the new fluoroquinolones are at least as effective as, and may be slightly more effective than, comparator antibiotics for the treatment of empiric CAP. Finally, our review did not point to any overall differences in terms of serious adverse effects, but these would be unlikely to occur in relatively small studies.

Project page URL
https://www.ccohta.ca/

URL for DARE abstract
http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12002008081

INAHTA brief and checklist

Indexing Status
Subject indexing assigned by CRD

MeSH
Community-Acquired Infections; Costs and Cost Analysis; Pneumonia

Language Published
English, French

Country of organisation
Canada

Address for correspondence
AccessionNumber
32002000301

Date bibliographic record published
15/02/2002

Date abstract record published
15/02/2002